News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|August 7, 2015

Pancreatic Cancer: A Caregiver's Perspective

Episodes in this series

EP. 1 What Pancreatic Cancer Is and The Risk Factors

EP. 1 What Pancreatic Cancer Is and The Risk Factors

EP. 2 A Cancer Patient's First-Hand Account of a Pancreatic Cancer Diagnosis

EP. 2 A Cancer Patient's First-Hand Account of a Pancreatic Cancer Diagnosis

EP. 3 Blood Tests, Biopsies, and Symptoms

EP. 3 Blood Tests, Biopsies, and Symptoms

EP. 4 Treatment Options for Pancreatic Cancer

EP. 4 Treatment Options for Pancreatic Cancer

EP. 5 Research for Pancreatic Cancer

EP. 5 Research for Pancreatic Cancer

EP. 6 Pancreatic Cancer: Staying Positive

EP. 6 Pancreatic Cancer: Staying Positive

EP. 7 Top Tips for Pancreatic Cancer Patients

EP. 7 Top Tips for Pancreatic Cancer Patients

EP. 8 Pancreatic Cancer: A Caregiver's Perspective

EP. 8 Pancreatic Cancer: A Caregiver's Perspective

EP. 9 Pancreatic Cancer: Coping With the Disease

EP. 9 Pancreatic Cancer: Coping With the Disease

Newsletter

Stay up to date on cancer updates, research and education

Related Content

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

ByJason Broderick

December 8th 2025

Dr. Robert Orlowski, chairman, Ad Interim; director of Myeloma; and professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

ByDr. Robert Orlowski

December 8th 2025

Georgia Hurst is a fierce patient advocate for those with Lynch syndrome. Catch up on all of Georgia's blogs here!

What I Want You to Know about Lynch Syndrome

ByGeorgia Hurst

December 8th 2025

CLL

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

ByJason M Broderick

December 7th 2025

follicular lymphoma

Epkinly Combo Effective in Second-Line R/R Follicular Lymphoma

December 7th 2025

Trending on CURE

A New Option Without Traditional Chemotherapy for Ph+ ALL

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

Elrexfio Maintains Responses in Elderly, Frail Patients With Multiple Myeloma

Epkinly Combo Effective in Second-Line R/R Follicular Lymphoma

© 2025 MJH Life Sciences^®

All rights reserved.